The expression of potassium ion channel subunit 1.2 (Kv1.2) in the dorsal root ganglion (DRG) influences the excitability of neurons, which contributes to the induction and development of neuropathic pain (NPP); however, the molecular mechanisms underlying the downregulation of Kv1.2 in NPP remain unknown. Histone deacetylase (HDAC) inhibitors are reported to attenuate the development of pain hypersensitivity in rats with NPP. Whether HDAC inhibitors contribute to regulation of Kv1.2 expression, and which specific HDAC subunit is involved in NPP, remain unexplored. In this study we established a chronic constrictive injury (CCI) model and used western blot, quantitative real-time PCR, immunostaining, intrathecal injection, and siRNA methods to explore which HDAC subunit is involved in regulating Kv1.2 expression to mediate NPP. Our results demonstrated that nerve injury led to upregulation of HDAC1 expression in the DRG, and of HDAC2 in the DRG and spinal cord. Double-labeling immunofluorescence histochemistry showed that Kv1.2 principally co-localized with HDAC2, but not HDAC1, in NF200-positive large neurons of the DRG. Intrathecal injection with the HDAC inhibitor, suberoylanilide hydroxamic acid, attenuated mechanical and thermal hypersensitivity and reversed the decreased expression of Kv1.2 in rats with CCI. Furthermore, treatment with HDAC2, but not HDAC1, siRNA also relieved mechanical and thermal hypersensitivity and upregulated the Kv1.2 expression in this model. In vitro transfection of PC12 cells with HDAC2 and HDAC1 siRNA confirmed that only HDAC2 siRNA could regulate the expression of Kv1.2. These findings suggest that HDAC2, but not HDAC1, is involved in NPP through regulation of Kv1.2 expression.
Introduction
Neuropathic pain (NPP) resulting from central or peripheral nervous system damage or dysfunction is characterized by spontaneous pain, hyperalgesia and allodynia(James N. Campbell1, 2006 , Colloca et al., 2017 . Patients often experience a number of different sensations, such as burning and electrical-like feelings, as well as pain resulting from non-painful stimulation (such as light touching). Chronic NPP has a strong negative impact on daily life (Attal et al., 2011) and is difficult to cure, with the clinical efficacy of current treatments very limited. Multiple causes of NPP have been described and its mechanism requires further exploration. The dorsal root ganglion (DRG) consists of first-order neurons in the nociceptive afferent pathway; hence, increased excitability of neurons in the DRG may mediate the development and maintenance of pain. Ion channels directly effect the excitability of DRG neurons. One of the mechanisms underlying NPP is peripheral nerve injury, which causes long-lasting changes in ion channel expression in the first-order sensory neurons of the DRG (Waxman and Zamponi, 2014 , Tibbs et al., 2016 , Colloca et al., 2017 . DRG neurons express a variety of ion channels, including voltage-gated potassium ion (Kv) channels, which selectively allow the passage of potassium ions across cell membranes and are the most common and most complex class of ion channels (DEVOR, 1983 , Rasband et al., 2001 , with an important role in the regulation of membrane potential and the excitability of nerve cells (Tombola et al., 2005, Waxman and Zamponi, 2014) . Peripheral nerve injury downregulates the expression of Kv subunit 1.2 (Kv1.2) in the DRG (Yang et al., 2004 , Chien et al., 2007 , Laumet et al., 2015 , which contributes to the induction of NPP; however, the molecular mechanisms underlying the downregulation of Kv1.2 remain unknown. Recent studies have focused on the fact that gene expression is also epigenetically regulated through chromatin remodeling and altered transcriptional regulation (Descalzi et al., 2015 , Tran et al., 2015 . Histone acetylation, one type of epigenetic modification, has been implicated in synaptic plasticity (Guan et al., 2009) and chronic NPP (Descalzi et al., 2015) . Moreover, histone deacetylase (HDAC) overexpression in neurons reduces dendritic spine density, synapse number, synaptic plasticity, and memory formation (Guan et al., 2009 , Kim et al., 2010 . Intrathecal injection with a HDAC inhibitor attenuates mechanical and thermal hypersensitivity in animal models with partial sciatic nerve ligations and L 5 spinal nerve transections (Denk et al., 2013) . The non-selective HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), relieves inflammatory (Chiechio et al., 2009 , Bai et al., 2010 and neuropathic (Matsushita et al., 2013 , Maiaru et al., 2016 pain in rats. Injection with SAHA can also attenuate nociceptive behavior in the second phase of the formalin test (Chiechio et al., 2009) ; however, the mechanisms underlying the roles of HDAC and HDAC inhibitors in NPP remain unclear. Whether HDAC inhibitors contribute to regulation of Kv1.2 expression, and the A C C E P T E D M A N U S C R I P T specific HDAC subunit involved in this process, remain unknown. Therefore, in this study we established a chronic constrictive injury (CCI) model and used western blot, quantitative real-time PCR (qPCR), immunostaining, intrathecal injection, and siRNA methods to explore which HDAC subunit is involved in regulation of Kv1.2 in mediation of NPP.
Materials and methods

Animals
Male Sprague-Dawley rats (body weight: 180-250 g) housed in separate cages and exposed to a standard 12 h light-dark cycle and normal illumination were used in this study. All animal procedures were conducted in accordance with the guidelines of the National Institutes of Health and were approved by Zhengzhou University Animal Care and Use Committee.
Chronic constrictive injury (CCI) model
We established a CCI animal model according to the methods of Bennett and Xie (Xie, 1988) . Rats were anesthetized with 10% chloral hydrate (0.35 mL/100 g) by intraperitoneal injection. Left hind limbs were disinfected with iodophor and the mid-thigh sciatic nerves exposed by blunt dissection. Sciatic nerves were then separated using a glass needle and loosely ligated four times with 4-0 surgical wire. The distance between ligatures was approximately 1 mm. Incisions were closed in layers and rats returned to their cages (Cao et al., 2015a) . This surgical manipulation was not performed on the sciatic nerves of the sham control group.
Intrathecal injection
Drug was administered through implanted intrathecal catheters (Cao et al., 2015b) . After rats were anesthetized, incisions were made between lumbar vertebrae 5 (L 5 ) and 6 (L 6 ) to insert 21-gauge sterile needles into the ligamentum flavum. Some cerebrospinal fluid was extracted and then PE10 polyethylene tubes were implanted into the lumber enlargement and advanced approximately 2.5-3 cm, and the final location was confirmed by tail-flick test. Intrathecal injections were administered directly into lumbar spinal regions. After ascertaining the correct position, the PE10 polyethylene tube was immobilized onto the neck under the skin. Finally, the fascia and skin were fastened and the PE10 polyethylene tube washed with approximately 20 μL physiological saline solution. The recovery period following this surgical procedure was 5 days.
Behavior tests
Mechanical paw withdrawal thresholds (PWTs) were monitored using calibrated manual von Frey filaments (Stoelting, Kiel, Wl, USA). Rats were placed on a metal mesh and covered with an opaque plastic container for 30 min to acclimatize to the environment. A Von Frey monofilament was applied perpendicularly to the plantar surface of the hind paw, and a constant pre-determined force was delivered for 5 s.
A C C E P T E D M A N U S C R I P T
The response was considered positive during the application of the stimulus or after removal of the filament if the animal exhibited behaviors including swift paw withdrawal and licking or shaking of the paw. The "up-down" methodological approach was used to calculate mechanical sensitivity (Deuis et al., 2017) . The mean mechanical paw withdrawal threshold of sham control rats was approximately 15 g. To ensure that animals had normal tactile sensation, the mechanical pain threshold was determined on the day before surgery. Thermal paw withdrawal latencies (PWLs) were determined using the plantar test (Ugo Basile, Varese, Italy). Each rat was placed on a transparent glass plate with a radiant heat generator below for 30 min to acclimatize. The intensity of the light source of the machine was adjusted so that normal animals had a retraction latency of 12-15 s, and a cut-off time was set in advance to prevent animal tissue damage. The latency of withdrawal from the heat stimulus was measured three times, with each measurement ≥ 5 min apart, and the average of the three tests referred to as the PWL(K. Hargreaves, 1988) . The PWTs and PWLs of each rat were tested before, and on days 3, 7, and 14 after CCI surgery. PWTs and PWLs were also measured for seven consecutive days after drug infusion.
Drug treatment
SAHA (Sigma-Aldrich) was dissolved in 5% dimethyl sulfoxide (DMSO) in physiological saline and stored at -20°C. The control group was injected with the same concentration of DMSO in normal saline. SAHA was administered at concentrations of 0.05, 0.1, and 0.2 µg/µL. Intrathecal injection of SAHA (10 µL) was followed by a saline flush. Seven days after CCI, SAHA was intrathecally injected for 7 consecutive days.
Small interfering RNA (siRNA) HDAC1 siRNA (Santa Cruz, 270070, USA) and HDAC1 negative control siRNA (Santa Cruz, 37007, USA) were purchased from Santa Cruz Biotechology. HDAC2 siRNA and HDAC2 negative control siRNA (Sigma-Aldrich, USA) were purchased from Sigma-Aldrich. The negative control siRNA were mismatched sequence. Small interfering RNA (siRNA) was administered to rats or transfected into cells (see below). Before intrathecal injection, siRNA solution was thoroughly blended with Lipofectamine 3000™ (Invitrogen, USA) to increase cell membrane penetration. For CCI rats, siRNA (1 μg) was intrathecally injected into the spinal cord on days 7, 8, 9, 10, and 11 after surgery. Western blots were used to evaluate the knockdown effect on HDAC1 and HDAC2 protein levels. The sense of HDAC2 negative control siRNA is 5'-UUCUCCGAACGUGUCACGUTT-3' and antisense is 5'-ACGUGACACGUUCGGAGAATT-3'. The sense of HDAC2 siRNA is 5'-AGUGUUCGAUGGACUCUUUTT-3' and antisense is 5'-AAAGAGUCCAUCGAACACUTT-3'.
Cell culture and transfection
A C C E P T E D M A N U S C R I P T
PC12 cells (2 × 10 5 ) were cultured in high glucose Dulbecco's modified Eagle's medium (DMEM; Solarbio, Hyclone), supplemented with 5% fetal bovine serum (FBS, Gibco) and 1% antibiotics (Gibco) in 6-well plates. Cells were incubated at 37°C in a CO 2 incubator for 18-24 h until 60%-80% they reached confluence. Lipofectamine 3000™ (Invitrogen) was used to transfect siRNA into cells, according to the manufacturer's reverse transfection protocol. Briefly, 20-80 pmol siRNA duplex was diluted in 100 μL transfection medium without serum or antibiotics. Lipofectamine 3000™ (2 μL) was added to 100 μL transfection medium and mixed gently at room temperature for about 30 min. A negative scrambled stealth siRNA duplex was used as control. Cells were washed using Dulbecco's phosphate-buffered saline, and the transfection mixture added to cells and incubated for 6 h. After incubation, the transfection mixture was removed and replaced with DMEM for an additional 18-24 h incubation at 37ºC in a CO 2 incubator. Cells were then collected for western blot experiments.
Western blotting L 4 -L 6 DRG and spinal cord tissues were fully ground in lysis buffer A (10 mM Tris, 1 mM phenylmethylsulfonyl fluoride, 5 mM MgCl 2 , 5 mM EGTA, 1 mM DTT, 100 mM NP-40, 40 mM leupeptin, and 250 mM sucrose), and stored on ice for 30 min before centrifugation at 4°C for 15 min at 1000 g. Supernatants were collected, and the remaining sediment added to lysis buffer B (9.25 mM Tris, 150 mM 10% SDS, 1 mM Triton X-100) and sonicated for 4 × 10 s with a tissue disruptor, and then incubated on ice for 30 min. Samples were centrifuged at 1000 g for 15 min at 4°C to obtain supernatants, which contained nuclear protein. The protein concentration was then measured using a bicinchoninic acid protein assay (Solarbio, Beijing, China). Samples (30 μg total protein) were mixed with protein loading buffer (Solarbio, Beijing, China) and heated at 99°C for 5 min before loading onto 10% sodium dodecyl sulfate-polyacrylamide gels (CWBIO, China) for electrophoresis. Proteins were transferred onto polyvinylidene fluoride membranes (Immobilon®-P, Merck KGaA, Darmstadt, Germany) at 30 V and 4°C overnight. After being blocked in 3% bovine serum albumin (BSA) (Solarbio, Beijing, China) and incubated overnight at 4°C with primary antibody to HDAC1 (1:1000; catalog No. ab19845, Abcam), HDAC2 (catalog No. 2540, Cell Signaling Technology), H3 (catalog No. D151007, BBI Life Sciences), β-actin (Zhongshan Jinqiao, China), or Kv1.2 (catalog No. APC010AN1202, Alomone Labs), membranes were washed six times for 10 min each in tris-buffered saline and 1% Tween. Horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:1000, Jackson laboratories) were added and incubated for 2 h at room temperature. Signals were visualized after further washes using an enhanced chemiluminescence (ECL) prime kit and a FluorChem E (AlphaImager ProteinSimple, San Jose, CA, USA). Average blot density analysis was performed using ImageJ software. All nuclear protein bands were normalized to H3 and β-actin was used as the loading control for cytosolic proteins.
Immunofluorescence
A C C E P T E D M A N U S C R I P T
Normal rats were perfused with 200 mL physiological saline followed by 400 mL 4% paraformaldehyde at pH7.4. The spinal cord and L 4 -L 6 DRG samples were harvested, placed in 4% paraformaldehyde overnight, and then dehydrated through 20% and 30% sucrose solutions before embedding in optimal cutting temperature compound for sectioning (spinal cord at 25 µm and DRG at 16 µm) (Su et al., 2017) . Frozen sections were treated with blocking buffer (0.3% Triton X-100, 0.01 M phosphate buffer, 10% BSA) for 2 h at 37°C. The following primary antibodies were used for double-labeling; rabbit anti-HDAC1 (1:500; Abcam), rabbit anti-HDAC2 ( 
Quantitative real-time PCR (qPCR)
Total RNA from fresh spinal cord and DRG was extracted using a nucleic acid purification kit (AXYGEN), and the concentration and quality assessed using a NanoDrop 2000 UV-Vis spectrophotometer (Thermo Scientific) . Total RNA from each individual sample was reverse transcribed using a kit (GoScript TM Reverse Transcription System; Promega) following the manufacturer's instructions, to produce 20 μL of cDNA. For qRT-PCR, a fourfold dilution of the cDNA mixture, primers for amplification of HDAC1, HDAC2, and GAPDH, and GoTap qPCR Master Mix (Promega) were used. The melting curves of each sample were measured to ensure the specificity of products. PCR was performed as follows: 95°C for 2 min, and 40 cycles at 95°C for 15 s and 60°C for 60 s, followed by intrinsic melting. At least three independent experiments were performed for each condition. The sequences of primers used for qRT-PCR were as follows: HDAC1 primer pair: forward, 5-GTGGCCCTGGACACAGAGAT-3 and reverse, 5-GCTTGAAATCTGGTCCAAAGT-3; HDAC2 primer pair: forward, 5-CAACCTAACTGTCAAAGGTCACGC-3 and reverse, 5-TGAAGTCTGGTCCAAAATACTCGA-3.
Chromatin immunoprecipitation (ChIP)
ChIP assays were conducted using the ChromaFlash™ High-Sensitivity ChIP Kit (EPIGENTEK, Base Catalog # P-2027). All the steps of experiment were following the assay protocol. Rats' DRGs were homogenized and cross-linked with 1%
A C C E P T E D M A N U S C R I P T formaldehyde for 10 min at room temperature. Add 0.25 M glycine to terminated reactions and centrifuge at 5000 rpm for 5 min at 4°C. Carefully remove supernatant and resuspend the chromatin lysate by vortexing and sheared chromatin using probe-based sonication. For immunoprecipitation, the sample used the Histone H3 (Rabbit, Cell Signaling Technology) binding to the Assay Strip Wells. Non-Immune IgG are set up as the negative control. Input DNA was used as a positive control. The DNA fragments were purified and identified using PCR/real-time PCR with the Kcna2 primers in the following. 1F ATTGTCCTGGGAAACCGAGT, 1R CCGAGGGAGATGTGTTGCTA; 2F AGAAGCAGAAGGCAGGAGTG, 2R GGAGACAGGGGAGAGGGTAG; 3F CTCTCAAGCGCTCCTCAACT, 3R TGGGTTAGATCCCTGTGTCC; 4F CCGGGACACAGGGATCTAAC, 4R GGGAGCCGACTCTGCAGT; 5F GGACTGCAGAGTCGGCTC, 5R CAGCAGAATGCCGGACACT; 6F AAATCAGTGTCCGGCATTCT, 6R CCCATTCCATGCACTCTTCT.
Data analysis
All data were analyzed using Prism software, version 6.0 (Graph-Pad, La Jolla, CA). Data are presented as means ± SEM. For western blot and qPCR, one-way analyses of variances (ANOVAs) followed by Tukey's tests for multiple comparisons of groups were used to compare the results of data recorded from three or more groups. A two-way ANOVA with Bonferroni's multiple comparison test was used to analyze behavioral data, when appropriate. Student's t tests were used for comparisons between two groups. Main and interaction effects were considered significant at p < 0.05.
Results
Nerve injury upregulated the expression of HDAC1 in the DRG and HDAC2 in the DRG and spinal cord
The expression of HDAC1 and HDAC2 in NPP was examined in CCI rats, which are a well-characterized model of NPP. First, to determine the success of the CCI model, we examined mechanical pain and thermal pain thresholds at 3, 5, 7, and 14 days after CCI. The results showed that mechanical and thermal hyperalgesia occurred after CCI and was steadily maintained from days 7 to 14 ( Figure 1A , C). There was no significant between-group difference in mechanical and thermal pain thresholds on the contralateral side ( Figure 1B, D) . Next, we examined the protein and mRNA expression of HDAC1 and HDAC2. Western blot and qPCR were used to detect HDAC1 and HDAC2 expression at 3, 7, and 14 days after surgery. Quantification of western blot data using band density analysis in ImageJ software revealed a dramatic increase of HDAC1 expression in L 4 -L 6 DRG after CCI ( Figure 1E ). Similarly, HDAC1 mRNA upregulation was also observed in the DRG ( Figure 1G) ; however, the protein and mRNA levels of HDAC1 in the spinal cord did not change significantly ( Figure 1I , K).
CCI also enhanced the protein expression of HDAC2 until 14 days after CCI in the ACCEPTED MANUSCRIPT Figure 1F ) and spinal cord ( Figure 1J ), consistent with HDAC2 mRNA levels ( Figure 1H , L). Overall, our results demonstrate that CCI led to significant increases in the expression of HDAC1 in the DRG and HDAC2 in the DRG and spinal cord.
A C C E P T E D M A N U S C R I P T DRG (
The HDAC inhibitor, SAHA, attenuated mechanical and thermal hypersensitivity and reversed decreased expression of Kv1.2 after CCI
To investigate the relationship between HDAC and nociceptive response, the HDAC inhibitor, SAHA, or vehicle control (DMSO) were administered intrathecally into CCI rats. Mechanical PWTs and PWLs were recorded every day after injection with SAHA or DMSO until 14 days after CCI. SAHA at doses of 0.1 and 0.2 µg/µL significantly attenuated mechanical and thermal hypersensitivity after CCI injury (Figure 2A , C). There were no significant differences in data recorded from the contralateral side in each group ( Figure 2B, D) . Previous studies have shown that CCI leads to decreased expression of Kv1.2; however, the underlying epigenetic regulatory mechanisms remain unclear. Therefore, we determined whether HDAC inhibitor could influence the expression of Kv1.2 in the injured DRG or spinal cord. Intrathecal injection with the HDAC inhibitor, SAHA, reversed decreased expression of Kv1.2 in the DRG ( Figure 2E ) and spinal cord ( Figure 2F ). These data suggest that this HDAC inhibitor can affect Kv1.2 expression and attenuate hyperalgesia after CCI.
Kv1.2 co-localized with HDAC2, but not HDAC1, in the rat DRG
The non-selective HDAC inhibitor, SAHA, led to an increase of Kv1.2 expression after CCI; however, the specific deacetylase involved in this process remains unknown. Therefore, we determined the cellular distribution of HDAC1, HDAC2, and Kv1.2 in the DRG and spinal cord. We also performed double immunolabeling with IB4, NF200, CGRP, and GS in the DRG, and using NeuN, GFAP, and Iba1 in the spinal cord.
Confocal images revealed that HDAC1 and HDAC2 were predominantly localized in cell nuclei. In the DRG, HDAC1 was mainly expressed in glial cells (GS labeling) and small neurons, and seldom co-localized with NF200-positive large, myelinated non-nociceptive neurons ( Figure 3A) . Conversely, HDAC2 was predominantly present in NF200-positive cells ( Figure 3B ), along with Kv1.2 ( Figure 3E ). In the spinal cord, HDAC1 co-localized with GFAP-positive astrocytes and Iba1-positive microglia ( Figure 3C) ; however, HDAC2 was principally expressed in the neurons and did not co-localize with GFAP or Iba1 ( Figure 3D ). Double immunolabeling showed that Kv1.2 co-localized with HDAC2, but not HDAC1, in the DRG ( Figure 3F ). Co-localization of Kv1.2 with HDAC2 supports their potential interaction with one another.
Treatment with HDAC2 siRNA relieved mechanical and thermal hypersensitivity and upregulated Kv1.2 expression
A C C E P T E D M A N U S C R I P T
To further clarify the specific deacetylase involved in this process rats were treated with small interfering RNA targeting HDAC1 or HDAC2 following CCI. Intrathecal injection of HDAC2, but not HDAC1, siRNA increased PWTs and PWLs after CCI compared with the negative control group ( Figure 4A , C, E, G). There was no significant between-group difference in mechanical or thermal pain thresholds on the contralateral side ( Figure 4B, D, F, H) . Western blot analysis revealed a significant increase in the Kv1.2 protein level in the DRG ( Figure 4J ) and spinal cord ( Figure 4L ) after intrathecal injection with HDAC2 siRNA in CCI rats. In comparison, intrathecal injection with HDAC1 siRNA had no effect on Kv1.2 expression levels in DRG and spinal cord( Figure 4I, K) . These results suggest that HDAC2 siRNA attenuates nociceptive responses after CCI through upregulation of Kv1.2 expression.
We further tested the effect of HDACs on Kv1.2 in vitro by transfecting cells with HDAC1 or HDAC2 siRNA. The results of western blotting were consistent with those in vivo; HDAC2 siRNA treatment significantly increased Kv1.2 expression in PC12 cells ( Figure 4M , N). These findings confirm that HDAC2, but not HDAC1, can regulate Kv1.2 expression levels.
However, a great number of researches suggest that deacetylases mainly act on histones, lower the acetylation of histones, strengthen the binding between histone and DNA strand, and thus indirectly affect gene transcription. Therefore, we determined if CCI led to an enrichment of histone H3 at promoters of Kcna2 (the gene of Kv1.2). The purified DNA was used for PCR analysis with six primers for Kcna2 (F1, − 489/− 331 bp; F2, − 414/− 218 bp; F3, − 258/− 101 bp; F4, − 123/+ 84 bp; F5, + 65/+ 219 bp; F6, + 196/+ 396 bp). Moreover, the chromatin immunoprecipitation (ChIP) assay showed that H3 binds to fragments of F3 and F6, but not other fragments. These binding activities were strikingly increased in the injured DRG on day 7 after CCI compared to those after sham surgery ( Figure 5A , B). These data suggest that injury induces the higher binding between histone H3 and Kcna2 which repressive the expression of Kv1.2.
Discussion
Peripheral nerve injury is reported to decrease the expression of Kv1.2 in the DRG (Yang et al., 2004 , Chien et al., 2007 , Laumet et al., 2015 . In this study, we found that nerve injury upregulated the expression of HDAC1 in the DRG and HDAC2 in the DRG and spinal cord. Moreover, HDAC2, but not HDAC1, co-localized with Kv1.2 in the rat DRG, and intrathecal injection with HDAC2, but not HDAC1, siRNA attenuated mechanical and thermal hypersensitivity and reversed the decreased expression of Kv1.2 after CCI. These findings suggest that HDAC2 is involved in NPP through regulation of Kv1.2 expression.
The mechanism of Kv1.2 involvement in pain perception
Peripheral nerve injury downregulates the expression of Kv1.2 in the DRG (Yang et al., 2004 , Chien et al., 2007 , Laumet et al., 2015 , contributing to the induction of NPP. In this study, we also confirmed reduced levels of Kv1.2 expression in both the DRG and spinal cord of CCI rats. The number and function of Kv A C C E P T E D M A N U S C R I P T channels directly affect the excitability of various cells, including nerve cells. Nerve injury causes reduction of the relevant Kv current, which in turn leads to the increased excitability of neurons. This may be the pathological basis of NPP. Peripheral nerve injury increases the expression of Kcna2 (the gene encoding Kv1.2) antisense RNA in the injured DRG through activation of myeloid zinc finger protein 1 (Zhao et al., 2013, Waxman and Zamponi, 2014) . Li et al. observed that CCI led to an increase in the abundance of the transcription factor, C/EBPβ, thereby promoting a decrease in levels of Kv1.2 and μ opioid receptor (MOR) in the DRG . In this study we found that nerve injury upregulated the expression of HDAC, which likely represents another mechanism involved in reduction of Kv1.2 upon nerve injury, since HDAC inhibitor reversed the decreased expression of Kv1.2 after CCI in our study.
The mechanism of HDAC involvement in pain perception
Epigenetic suppression of potassium-chloride co-transporter 2 (KCC2) gene expression in the spinal cord by HDAC-mediated histone deacetylation results in persistent inflammatory pain (Lin et al., 2017) . Accumulating evidence suggests that HDAC inhibitors modulate both acute and chronic pain (Denk et al., 2013 , Hou et al., 2017 , Sanna et al., 2017 , and they are reported to improve the mechanical hypersensitivity to bone cancer pain in rats, and increase the analgesic effects of morphine by restoring the expression of MOR in the spinal cord (Hou et al., 2017) . Moreover, HDAC inhibitors can enhance the expression of the mGlu2 receptor in the DRG, leading to analgesia (Chiechio et al., 2009) . Our results also demonstrate that intrathecal injection with the non-selective HDAC inhibitor, SAHA, attenuated mechanical and thermal hypersensitivity in CCI rats. Therefore, HDAC inhibition may provide a therapeutic avenue for NPP caused by nerve injury, and other diseases; however, the clinical application of non-selective HDAC inhibitors is associated with a range of side effects, which limit their usefulness for treatment of pain.
Identification of the specific HDAC family member(s) involved in NPP will help to elucidate the epigenetic regulatory mechanisms involved in pain and lead to the development of more selective HDAC inhibitors for application in pain relief. To further clarify the specific deacetylase involved in NPP, we examined the role of siRNAs targeting HDAC1 or HDAC2 after CCI. Intrathecal injection with HDAC2, but not HDAC1, siRNA ameliorated the pain threshold effects in CCI rats. These data indicate that treatment with HDAC2 siRNA is an effective alternative method for pain relief.
HDAC2 siRNA regulates Kv1.2 to relieve pain
To further investigate the relationship between Kv1.2 and HDACs, we used double-labeling immunofluorescence histochemistry to observe the cellular distribution of HDAC1, HDAC2, and Kv1.2 in the DRG and spinal cord.
Immunostaining results demonstrated that Kv1.2 co-localized with HDAC2, but not HDAC1, in the DRG. This result supports the possibility of HDAC2 involvement in regulation of Kv1.2. Furthermore, intrathecal injection with HDAC2 siRNA reversed the decrease in Kv1.2 expression after CCI; however, intrathecal injection with HDAC1 siRNA had no effect on Kv1.2. In vitro, HDAC2 and HDAC1 siRNA were transfected into PC12 cells, demonstrating that only HDAC2 could regulate the expression of Kv1.2. These findings suggest that HDAC2, but not HDAC1, modulates
A C C E P T E D M A N U S C R I P T
Kv1.2 expression to mediate NPP. Our results also provide evidence supporting further research to investigate HDAC2 as a pain-relieving drug. The epigenetic mechanisms involved in pain are complex (Descalzi et al., 2015) . Some studies have shown that both acetylation and deacetylation inhibitors can contribute to pain relief. Knockdown of acetyltransferase in the DRG neurons of rats reduces histone acetylation and prevents chronic stress-induced increases in visceral pain (Hong et al., 2015) . In addition, HDAC inhibitors can attenuate the development of hypersensitivity in NPP models (Denk et al., 2013) . It is possible that these apparently contradictory results indicate the existence of different molecular mechanisms. However, the specific mechanism involved remains unclear. In this study, consistent with previous reports, our results demonstrate that the HDAC inhibitor, SAHA, and HDAC2 siRNA can relieve the nociceptive response in CCI rats. Furthermore, both SAHA and HDAC2 siRNA could reverse the decreased expression of Kv1.2 in CCI rats. A mechanism where HDAC2 regulates Kv1.2 expression would provide theoretical support for the future application of HDAC2 inhibitors in pain relief.
Conclusions
In summary, this study explored the epigenetic mechanisms underlying NPP. To the best of our knowledge, we provide the first evidence that nerve injury upregulates the expression of HDAC1 in the DRG and HDAC2 in the DRG and spinal cord, and that HDAC2 could provide a prospective treatment for NPP through regulation of Kv1.2 expression.
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A C C E P T E D M A N U S C R I P T The expression of HDAC1 and HDAC2 were measured by western blot and qPCR in the spinal cord. *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham; one-way ANOVA; n = 4 rats per group. (A-D) PWTs and PWLs were evaluated every day after injection with SAHA or DMSO until 14 days after CCI. SAHA (0.1 and 0.2 µg/µL) significantly attenuated mechanical and thermal hypersensitivity after CCI injury. *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham; two-way ANOVA; n = 6 rats per group. (E, F) Western blot data showing that the decreased expression of Kv1.2 after CCI in the DRG and spinal cord was reversed by SAHA. *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham; # P < 0.05 vs. CCI; one-way ANOVA; n = 4 rats per group. PWTs and PWLs were evaluated after injection with HDAC1 siRNA or HDAC1 (negative control) NC after CCI. **P < 0.01, ***P < 0.001 vs. CCI + HDAC1 NC; two-way ANOVA; n = 5 rats per group. (E-H) PWTs and PWLs were evaluated after injection with HDAC2 siRNA or HDAC2 NC after CCI. **P < 0.01, ***P < 0.001 vs. CCI + HDAC2 NC; two-way ANOVA; n = 5 rats per group. (I-L) Western blot data showing that the decreased expression of Kv1.2 after CCI in the DRG and spinal cord was reversed by intrathecal injection with HDAC2 siRNA (J, L), but not HDAC1 siRNA (I, K). (M, N) The expression of Kv1.2 was increased after HDAC2 siRNA was transfected into PC12 cells (N). In comparison, intrathecal injection with HDAC1 siRNA had no effect on Kv1.2 expression (M). *P < 0.05, **P < 0.01, ***P < 0.001 vs. sham; # P < 0.05 vs. NC; one-way ANOVA; n = 4 per group. 
